ARCHIVES

Bevacizumab And Irinotecan May Increase Survival Of GBM

This article is from The Cancer Letter archive.

Vol. 30 No. 10 | October 26, 2007

Download PDF Visit The Full Archive

Related Articles

After Congressional Inquiry, NCI Posts Ambiguous Statement On Abortion And Breast Cancer Risk

December 13, 2002

DCT’s Experimental Therapeutic Program Outlined to Board

May 2, 1975

FDA will return memento given to McClellan by NCI Director Andrew von Eschenbach.

February 6, 2004

Other Institutes Fare Well With ’77 Appropriations

August 20, 1976

In Brief: Interim Money Bill Passes; NCI Can Start Awarding Grants, Contract With 1980 funds, Until Nov. 20

October 26, 1979

Zeneca Buys 50% Stake In Salick, Gets Managed Care Access

January 6, 1995